子宮內膜異位症：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 德國子宮內膜異位症市場預計將從 2025 年的 1.24 億美元成長到 2035 年的 4.14 億美元，這反映了受新型荷爾蒙療法普及推動的強勁兩位數成長。
• 市場擴張受以下因素支撐：
• 擴大口服 GnRH 拮抗劑和先進荷爾蒙療法的應用。
• 診斷和治療率的提高
• 儘管患者數量成長緩慢，但由於治療週期長且存在高價治療方法，市場規模正在擴大。
• 未來的成長取決於能夠持續緩解症狀並降低復發率的疾病修正治療的研發。

子宮內膜異位症概述

子宮內膜異位症是一種雌激素依賴性的慢性全身性發炎疾病，其特徵是子宮內膜樣組織出現在卵巢腔以外的部位。這些異位病灶最常位於骨盆腔腹膜、卵巢和子宮薦骨韌帶，並分為三種主要表現型：淺層腹膜子宮內膜異位症、卵巢子宮內膜異位症和深部浸潤性子宮內膜異位症（DIE），後者可擴散至腸道和膀胱等器官。此疾病的進展與異位組織的周期性雌激素依賴性活動有關，導致反覆出血、慢性發炎、纖維化和粘連形成。臨床上，它表現為嚴重的慢性骨盆疼痛、月經、性交疼痛和不孕，嚴重影響患者的生活品質。特別是，由於疾病的嚴重程度與 ASRM 分類等分期系統沒有一致的相關性，因此越來越傾向於基於症狀、影像學支持的診斷。

目前尚無根治性治療方法，治療重點在於長期控制症狀。治療方法包括手術切除病灶和抑制雌激素生成的荷爾蒙療法，例如黃體素和促性腺激素釋放激素拮抗劑（如依拉戈利克斯、瑞盧戈利克斯）。儘管有多種治療選擇，但復發和症狀控制不佳的情況仍然很常見，表明仍有未被滿足的醫療需求。

主要亮點

• 在美國，由於人們意識的提高和診斷技術的改進，有症狀病例的數量預計將從 2025 年的 441 萬例增加到 2035 年的 472 萬例，呈現穩定成長（年複合成長率為 0.7%）。
• 這種疾病的診斷往往存在嚴重延誤，且症狀多種多樣，因此難以進行有效的疾病管理。
• 缺乏根治性治療方法和高復發率凸顯了對更持久、更有針對性的治療方案的迫切需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Kissei Pharmaceutical Co., Ltd.
• Hope Medicine（Nanjing）Co., Ltd.
• Organon and Co
• Gesynta Pharma AB
• Nanjing Chia-tai Tianqing Pharmaceutical
• AbbVie
• Sumitomo Pharma Switzerland GmbH
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Jiangsu HengRui Medicine Co., Ltd.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Endometriosis Market Outlook

Thelansis's "Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Endometriosis Overview

Endometriosis is a chronic, estrogen-dependent, systemic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. These ectopic lesions most commonly localize to the pelvic peritoneum, ovaries, and uterosacral ligaments, and are classified into three major phenotypes: superficial peritoneal endometriosis, ovarian endometriomas, and deep infiltrating endometriosis (DIE), which can involve organs such as the bowel and bladder. The disease is driven by cyclic, estrogen-mediated activity of ectopic tissue, leading to recurrent bleeding, chronic inflammation, fibrosis, and adhesion formation. Clinically, this manifests as severe chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility, significantly impairing quality of life. Notably, disease severity does not consistently correlate with staging systems such as the ASRM classification, prompting a shift toward symptom-driven and imaging-supported diagnosis.

There is currently no definitive cure, and management is centered on long-term symptom control. Treatment approaches include surgical intervention for lesion excision and hormonal therapies aimed at suppressing estrogen production, such as progestins and GnRH antagonists (e.g., elagolix, relugolix). Despite available options, recurrence and suboptimal symptom control remain common, underscoring persistent unmet need.

Key Highlights

• In the US, symptomatic cases are projected to increase from 4.41M in 2025 to 4.72M by 2035, reflecting steady growth (0.7% CAGR) driven by improved awareness and diagnosis.
• The disease is associated with substantial diagnostic delays and heterogeneous presentation, complicating effective disease management.
• Lack of curative therapies and high recurrence rates highlight a significant unmet need for more durable and targeted treatment options.

Market Overview

• The Germany endometriosis market is projected to grow from $124M in 2025 to $414M by 2035, reflecting strong double-digit growth driven by uptake of novel hormonal therapies.
• Market expansion is supported by:
• Increasing adoption of oral GnRH antagonists and advanced hormonal treatments
• Improved diagnosis and treatment rates
• Despite moderate patient growth, market value is driven by chronic treatment duration and premium-priced therapies.
• Future growth will depend on the development of disease-modifying therapies that provide sustained symptom relief and reduce recurrence rates.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Kissei Pharmaceutical Co., Ltd.
• Hope Medicine (Nanjing) Co., Ltd.
• Organon and Co
• Gesynta Pharma AB
• Nanjing Chia-tai Tianqing Pharmaceutical
• AbbVie
• Sumitomo Pharma Switzerland GmbH
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Jiangsu HengRui Medicine Co., Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)